Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program

December 16, 2025 updated by: Narongkorn Saiphoklang, MD, Thammasat University
This study is a cross-sectional study. The study aims to determine the levels of immunity against hepatitis B virus and varicella-zoster virus in medical students.

Study Overview

Status

Completed

Conditions

Detailed Description

This study is a cross-sectional study aimed at determining the levels of immunity against the hepatitis B virus and varicella virus in medical students. Additionally, it aims to compare the rate of increase in immunity levels before and after receiving the hepatitis B and varicella-zoster vaccines in medical students. Medical students aged 18 years or older are included in the study.

Study Type

Observational

Enrollment (Actual)

401

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
    • Changwat Pathum Thani
      • Pathum Thani, Changwat Pathum Thani, Thailand, 12120
        • Narongkorn Saiphoklang

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Medical students aged 18 years or older are included.

Description

Inclusion Criteria:

  • Medical students
  • Age 18 years or older

Exclusion Criteria:

  • Known cases of hepatitis B virus infection
  • Known cases of varicella-zoster virus infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Medical students
Medical students aged 18 years or older

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The seroprevalence of hepatitis B virus
Time Frame: From enrollment to the end of treatment at 6 months
The immunity level against the hepatitis B virus is assessed.
From enrollment to the end of treatment at 6 months
The seroprevalence of varicella-zoster virus
Time Frame: From enrollment to the end of treatment at 6 months
The immunity level against varicella-zoster virus is assessed.
From enrollment to the end of treatment at 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The vaccination rate of hepatitis B virus
Time Frame: From enrollment to the end of treatment at 6 months
The vaccination rate of hepatitis B virus is assessed.
From enrollment to the end of treatment at 6 months
The vaccination rate of varicella-zoster virus
Time Frame: From enrollment to the end of treatment at 6 months
The vaccination rate of varicella-zoster virus is assessed.
From enrollment to the end of treatment at 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Thammasat University

Collaborators

Thammasat University Hospital

Investigators

  • Principal Investigator: Narongkorn Saiphoklang, MD, Thammasat University Faculty of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2025

Primary Completion (Actual)

August 31, 2025

Study Completion (Actual)

November 30, 2025

Study Registration Dates

First Submitted

March 22, 2025

First Submitted That Met QC Criteria

March 22, 2025

First Posted (Actual)

March 28, 2025

Study Record Updates

Last Update Posted (Actual)

December 23, 2025

Last Update Submitted That Met QC Criteria

December 16, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MTU-EC-SA-0-159/67

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD and documents will be available for sharing immediately after publication for a period of 2 years.

IPD Sharing Time Frame

IPD and documents will be available for sharing immediately after publication for a period of 2 years.

IPD Sharing Access Criteria

All researchers will be able to access the IPD and supporting information via the repository website without restriction.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe